Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 219

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 219
---

authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the
instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and
whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed
to our own Common Stock and whether the instrument holders could potentially require “net cash settlement” in a circumstance
outside of our control, among other conditions for equity classification. This assessment, which requires the use of professional judgment,
was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management
has concluded that the Public Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment.

Common Stock Subject to Possible Redemption

We account for our Common
Stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.”
Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable
common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption
upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common
stock is classified as stockholders’ equity. Our Common Stock features certain redemption rights that are considered to be outside
of our control and subject to occurrence of uncertain future events. Accordingly, Common Stock subject to possible redemption is presented
as temporary equity, outside of the stockholders’ deficit section of our balance sheets. We recognize changes in redemption value
immediately as they occur and adjust the carrying value of redeemable common stock to equal the redemption value at the end of each reporting
period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital
and accumulated deficit.

Net Loss per Common Share

Net loss per share is computed
by dividing net loss by the weighted average number of shares of common stock outstanding during the period. At December 31, 2023, we
did not have any dilutive securities and/or other contracts that could, potentially, be exercised or converted into shares of common
stock and then share in our earnings. As a result, diluted net loss per share is the same as basic net loss per share for the period
presented.

<div align='center'>127</div